Advertisement
Advertisement
U.S. markets close in 3 hours 29 minutes
Advertisement
Advertisement
Advertisement
Advertisement

SELLAS Life Sciences Group, Inc. (SLS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.3100-0.2900 (-8.06%)
As of 12:26PM EDT. Market open.
Advertisement
Sign in to post a message.
  • J
    Joe
    Metastatic ovarian cancer patients are at the end, cancers returned after multiple rounds of surgery, radiation chemo and platinum based chemo - run through the mill, And all GPs Patients have survived already for as long as the SOC avg duration OS of 9 months. 100% Guaranteed the Joint Analysis can only improve on what is already better given Gps pristine safety profile. This Phase 2 data will be heralded world wide as a potential new therapy offering hope for these dying patients.
    Anecdotally, we know from prior pr, just the first patient has already survived for over 2 years - avg PROC life expectancy is 9 / 10 months. 24+ months vs 9/10 --- And for those patients whose immune system respond strongly will potentially be cured like many other trials.

    Do not get scammed by the short spammers obfuscating valuable facts.
  • C
    Cured
    Joint Merck Analysis Data by the end of June - last year SLS traded up to 15 ahead of this readout. Metastatic ovarian cancer patients are at the end, cancers returned after multiple rounds of surgery, radiation chemo and platinum based chemo - run through the mill, And all GPs Patients have survived already for as long as avg duration of 9 months. The Joint Analysis can only improve on what is already better given Gps pristine safety profile. This Phase 2 data will be heralded world wide as a potential new therapy offering hope for these dying patients.
    Anecdotally, we know from prior pr, just the first patient has already survived for over 2 years - avg PROC life expectancy is 9 / 10 months. 24+ months vs 9/10 --- And for those patients whose immune system respond strongly will potentially be cured like many other trials.

    Joint Merck Analysis Data by the end of June
    Bullish
  • j
    james
    You know Gps works when the Chairman of MD Andersons Leukemia Dept Requests Expanded Access - he sees actual data from 2 Gps Trials. In the ‘Leukemia Insight’ Bulletin of Oct 2021 published by MD Anderson Cancer Center of University of Texas, the Authors summarize the immune and cellular therapy clinical trials currently available for patients with acute myeloid leukemia (AML) at the MD Anderson Cancer Center Institution Dept. of Hematology, led by Prof K.

    https://www.mdanderson.org/documents/Departments-and-Divisions/Leukemia/Leukemia%20Insights%20Newsletter_October%202021%20AML.pdf

    Interestingly they write ‘Galinpepimut-S is a peptide vaccine against the protein WT-1 that is highly expressed on leukemia cells and may help generate immune responses against leukemia. It is being evaluated as maintenance therapy, as well as in combination with the checkpoint inhibitor pembrolizumab as salvage therapy in patients with relapsed/refractory AML’.

    The fact that Prof K. is trialing GPS in combination with pembrolizumab for relapsed/refractory AML as a salvage therapy for relapsed disease after CR1 (in order to achieve CR2) is something new and it confirms the message shared during the Aug 17th webinar in 2021 by Prof Levy who provided the rational for a possible GPS patient population expansion.

    reposting for anyone who doesn't know
    - and for the spamming short scammers
  • C
    Cured
    Listen back to the April shareholder Call Re Merck Data Analysis to confirm Immune response correlated to Overall Survival. Once this is out SLS will be worth a Factor of 10 more in Value: InMyOpinion
    Combination with the checkpoint inhibitor Keytruda® to treat patients diagnosed with second- or third-line WT1(+) relapsed or refractory platinum-resistant, advanced metastatic ovarian cancer.
    - patients in this study, nearly 67% had failed second-line therapies or were refractory, and all were resistant to the standard of care platinum-based therapy. They were expected to survive 9 to 10* months.
    An ad hoc analysis at 15-week follow-up showed that nearly 64% of the patients were stable or are responding to the combination therapy. More than nine months after their initial treatment, all 11 are still alive. Median overall survival, therefore, remains unknown.
    -
    100% Guaranteed to Report Survival Data better than all Existing Therapies for patients who have exhausted all options.
    Same As $NKTX 2 weeks ago, reported data for 5 patients in a P1, added a Half Billion in Market cap - SLS trades for $50M / ? for how much longer ?

    Merck Uncorks the Data in June
    Bullish
  • j
    james
    Through my years of working in cancer immunotherapy, I have witnessed great advances in the field, and I believe SELLAS is on the verge of such an advance. I have been impressed with the significant potential of the Company’s lead product, galinpepimut-S, to successfully treat hematological and solid malignancies through a unique approach of peptide-based immunization against the WT1 oncoprotein,” stated Dr. Weber.
    https://bit.ly/3IWSu2L
    Bullish
  • C
    Cured
    SLS traded up to $15 ahead of the last ad hoc prelim data. Now we will see a mature, larger Joint analysis with MRK that is Literally Guaranteed to Report Survival results that far surpass all other agents, in practice and clinic. Understanding known facts and logical deduction requires GPs to exceed all other agents “GPS is a Wilms Tumor-1 (WT1)-targeting peptide immunotherapeutic. For the ovarian cancer study, it was used in combination with the checkpoint inhibitor Keytruda® to treat patients diagnosed with second- or third-line WT1(+) relapsed or refractory platinum-resistant, advanced metastatic ovarian cancer.
    - patients in this study, nearly 67% had failed second-line therapies or were refractory, and all were resistant to the standard of care platinum-based therapy. They were expected to survive 9 to 10* months.
    An ad hoc analysis at 15-week follow-up showed that nearly 64% of the patients were stable or are responding to the combination therapy. More than nine months after their initial treatment, all 11 are still alive. Median overall survival, therefore, remains unknown.”

    $7 to $20 in a day $NKTX is a good example of the Markets reaction to a potential meaningful therapy for End Stage Cancer patients who have exhausted all options, + $600M in MC based on a 5 patient cohort in a P1 - because these patients were dying, had no other options, exactly the same kind of patients in BOTH of the GPS combinations.
  • C
    Chari
    Stock was unreasonably taken down after the offering on April 1. Its now catching up quickly.
  • J
    Joe
    What will the Price Be PreMarket the Moment the Keytruda Results are released? $13 is My guess.
    Also - If GPs Keytruda Survival Data far surpassing all existing treatments is not 100% Guaranteed, can just one of the many short lowlife > logically < explain why not? No Distortion allowed!
    Bullish
  • j
    james
    You know Gps works when the Chairman of MD Andersons Leukemia Dept Requests Expanded Access to Gps. - he sees actual data from 2 Gps Trials. In the ‘Leukemia Insight’ Bulletin of Oct 2021 published by MD Anderson Cancer Center of University of Texas, the Authors summarize the immune and cellular therapy clinical trials currently available for patients with acute myeloid leukemia (AML) at the MD Anderson Cancer Center Institution Dept. of Hematology, led by Prof K.

    https://www.mdanderson.org/documents/Departments-and-Divisions/Leukemia/Leukemia%20Insights%20Newsletter_October%202021%20AML.pdf

    Interestingly they write ‘Galinpepimut-S is a peptide vaccine against the protein WT-1 that is highly expressed on leukemia cells and may help generate immune responses against leukemia. It is being evaluated as maintenance therapy, as well as in combination with the checkpoint inhibitor pembrolizumab as salvage therapy in patients with relapsed/refractory AML’.

    The fact that Prof K. is trialing GPS in combination with pembrolizumab for relapsed/refractory AML as a salvage therapy for relapsed disease after CR1 (in order to achieve CR2) is something new and it confirms the message shared during the Aug 17th webinar in 2021 by Prof Levy who provided the rational for a possible GPS patient population expansion.
    Bullish
  • j
    james
    Through my years of working in cancer immunotherapy, I have witnessed great advances in the field, and I believe SELLAS is on the verge of such an advance. I have been impressed with the significant potential of the Company’s lead product, galinpepimut-S, to successfully treat hematological and solid malignancies through a unique approach of peptide-based immunization against the WT1 oncoprotein,” stated Dr. Weber.
  • J
    Joe
    $SLS Fair question: If Gps opens up the Ovarian cancer market to Merck, 20,000 US patients - $2B in annual revenue, isn't Gps worth more than a $60 m market cap? - whoops $70M now... same point though.
    and we know the June data is 100% Guaranteed to report overall survival results that Far Surpass all other therapies.
  • A
    Anonymous
    i'm hoping and praying that this trend of stock price increases continues until the data is released.
  • S
    Stephens
    Jazz bought CPXX for $1.5B when it released its P3 AML data - 3,000% More than SLS trades for now. Gps Phase 3 AML Fda approval less than 12 months out unless the IDMC halts the trial sooner, which is very likely when you think of all the time, 30 months deep into a trial where Control patients only survive 5 months.

    Gps is a better drug than the cpxx drug too, it treats 20 different cancers.
  • p
    peter
    "SELLAS Life Sciences Launches Expanded Access Program for Galinpepimut-S." This is by itself, very telling that they have a game changing agent that these high level cancer center oncologists have requested be made available, prior FDA approval, for thier terminal patients. Pretty sure they are seeing impressive theraputic results or why would this even be considered. I am very bullish for data readouts end of June. Go Longs.
    Bullish
  • C
    Cured
    2 Billion dollar data hits next month and SLS trades for .07 cents on the dollar.
  • C
    Cured
    Unlikely the Phase 3 will continue to completion/ Moffitt Center Phase 2 Gps patients survived 21 months on average vs only 5.4 with the Best Available Treatment. P3 Identical controls and Gps Investigators have requested Expanded Access for additional settings. 27 months deep into a trial with cg patients 5 months, A Halt for Efficacy is Likely.
    Bullish
  • C
    Cured
    All Gps Keytruda patients remained alive 9+months, which already equal to the avg Os duration with SOC.
    It is 100% guaranteed, Os will far surpass existing therapy for these End Stage Ovarian Cancer Patients.
    Two weeks ago NKTX added $500M on the strength of a 5 patient cohort, P1 trial - mostly because the patients have no other options, same as the end stage Ovarian and Mesothelioma cancer patients in the Gps Keytruda and Opdivo trials.

    SlS could be a $500M market cap bio in a blink come June.
    Bullish
  • P
    P509$
    Immunomedics is the path SLS is on. Similar immunotherapy Phase 3 was stopped early, price went from 2 to $80.
  • R
    Ronald
    Nice increase in the share price but the increase in volume is what is encouraging.
  • j
    james
    You know Gps works when the Chairman of MD Andersons Leukemia Dept Requests Expanded Access to Gps. - he sees actual data from 2 Gps Trials. In the ‘Leukemia Insight’ Bulletin of Oct 2021 published by MD Anderson Cancer Center of University of Texas, the Authors summarize the immune and cellular therapy clinical trials currently available for patients with acute myeloid leukemia (AML) at the MD Anderson Cancer Center Institution Dept. of Hematology, led by Prof K.

    https://www.mdanderson.org/documents/Departments-and-Divisions/Leukemia/Leukemia%20Insights%20Newsletter_October%202021%20AML.pdf

    Interestingly they write ‘Galinpepimut-S is a peptide vaccine against the protein WT-1 that is highly expressed on leukemia cells and may help generate immune responses against leukemia. It is being evaluated as maintenance therapy, as well as in combination with the checkpoint inhibitor pembrolizumab as salvage therapy in patients with relapsed/refractory AML’.

    The fact that Prof K. is trialing GPS in combination with pembrolizumab for relapsed/refractory AML as a salvage therapy for relapsed disease after CR1 (in order to achieve CR2) is something new and it confirms the message shared during the Aug 17th webinar in 2021 by Prof Levy who provided the rational for a possible GPS patient population expansion.
    Bullish
Advertisement
Advertisement